RxDoctor Payments DataLook up a doctor →

Priyadarshan Bajpayi, MD

Psychiatry · Massapequa, NYNPI 1699087148

Payments from drug & device makers

$297,294in general payments, 2019–2025

Across 1,931 payments — averaging $153.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$106K
  • Otsuka America Pharmaceutical, Inc.$43K
  • Johnson & Johnson$35K
  • Axsome Therapeutics, Inc.$35K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22K
  • AbbVie$22K
  • plus $36K from 35 others

What the payments were for

  • Consulting fees$35,54512%
  • Speaking & faculty fees$208,44670%
  • Travel & lodging$11,2334%
  • Food & beverage$41,74814%
  • Education$3220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$297,294 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$1,359,369
Medicare patients
785
Services billed
13,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl131$252,216
AustedoDeutetrabenazine11$157,849
RexultiBrexpiprazole44$64,424
CaplytaLumateperone Tosylate28$52,284
VraylarCariprazine Hcl22$31,132
LybalviOlanzapine/Samidorphan Malate12$20,362
TrintellixVortioxetine Hydrobromide28$19,029
MounjaroTirzepatide13$13,751
Lurasidone Hcl30$7,808
Adzenys Xr-OdtAmphetamine15$7,356
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$6,580
Jornay PmMethylphenidate Hcl13$5,600
Alprazolam ErAlprazolam42$3,904
Clonazepam488$3,717
Zolpidem Tartrate230$3,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$34,834$252,216131 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,824$157,84911 claims
Otsuka America Pharmaceutical, Inc.Rexulti$43,257$64,42444 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$21,740$52,28428 claims
AbbVieVraylar$21,604$31,13222 claims
Alkermes, Inc.Lybalvi$105,642$20,36212 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,906$19,02928 claims
Neos Therapeutics, LPAdzenys Xr-Odt$794$7,35615 claims
Ironshore Pharmaceuticals Inc.Jornay Pm$1,148$5,60013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →